Biosensors International Group has announced the appointment of Keith G Oldroyd to the post of chief medical officer. A press release from the company details that Oldroyd was a consultant interventional cardiologist at the West of Scotland Regional Heart and Lung Centre, Glasgow, UK, and has a career experience of more than 9000 percutaneous coronary intervention (PCI) procedures. He also has significant experience of both transcatheter aortic valve implantation (TAVI) and Mitraclip procedures.
Oldroyd holds a personal chair within the Institute of Cardiovascular and Medical Sciences, University of Glasgow and was the NHS Scotland Research Lead for CV Disease. His own research interests include the clinical and experimental assessment of novel drug eluting stents and the use of invasive physiological indices of stenosis severity to guide decision making in the cath lab. He has been a principal investigator in several international trials including FAME, FAME 2, PRAMI, LEADERS FREE, CULPRIT SHOCK and TWILIGHT, all of which have been published in the New England Journal of Medicine. In 2018, he received a Lifetime Achievement Award from the British Cardiovascular Intervention Society and in 2019 the Sir James McKenzie Medal from the British Cardiovascular Society.
In the press release, Oldroyd states: “I am delighted to be joining Biosensors at such a pivotal moment in the company’s development. Biosensors have a history of innovative drug and device development. They have also facilitated guideline changing clinical trials such as LEADERS FREE, which focused the minds of clinicians on the very poor outcomes after PCI in patients with high bleeding risk (HBR)” He adds: “The most exciting aspect of this next phase of my career is the opportunity to work with the world class team of engineers, designers and researchers assembled by Biosensors and of course the clinicians with whom the company collaborates in its clinical research programme.”
